These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 31501383)

  • 1. [Effect of Proteinuria in Patients Receiving Anti-VEGF Therapy for Advanced Colorectal Cancer].
    Kinugasa S; Horikawa M; Kawashima T; Monma H; Hori H; Kobayashi I; Takase S
    Gan To Kagaku Ryoho; 2019 Aug; 46(8):1334-1336. PubMed ID: 31501383
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical utility of routine proteinuria evaluation in treatment decisions of patients receiving bevacizumab for metastatic solid tumors.
    Yeh J; Frieze D; Martins R; Carr L
    Ann Pharmacother; 2010 Jun; 44(6):1010-5. PubMed ID: 20460557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biomarkers of anti-angiogenic therapy in metastatic colorectal cancer (mCRC): original data and review of the literature.
    Pohl M; Werner N; Munding J; Tannapfel A; Graeven U; Nickenig G; Schmiegel W; Reinacher-Schick A
    Z Gastroenterol; 2011 Oct; 49(10):1398-406. PubMed ID: 21964893
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Renovascular safety of bevacizumab in breast cancer patients. The prognostic value of hypertension and proteinuria].
    Launay-Vacher V; Janus N; Beuzeboc P; Daniel C; Ray-Coquard I; Selle F; Rey JB; Jouannaud C; Spano JP; Thery JC; Morere JF; Goldwasser F; Mir O; Oudard S; Scotté F; Dorent R; Ludwig L; Deray G; Gligorov J
    Bull Cancer; 2015 Nov; 102(11):906-14. PubMed ID: 26603517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation of hypertension and proteinuria with outcome in elderly bevacizumab-treated patients with metastatic colorectal cancer.
    Feliu J; Salud A; Safont MJ; García-Girón C; Aparicio J; Losa F; Bosch C; Escudero P; Casado E; Jorge M; Bohn U; Pérez-Carrión R; Carmona A; Custodio AB; Maurel J
    PLoS One; 2015; 10(1):e0116527. PubMed ID: 25602286
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bevacizumab-induced hypertension: pathogenesis and management.
    Syrigos KN; Karapanagiotou E; Boura P; Manegold C; Harrington K
    BioDrugs; 2011 Jun; 25(3):159-69. PubMed ID: 21627340
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does bevacizumab impact anti-EGFR therapy efficacy in metastatic colorectal cancer?
    Derangère V; Fumet JD; Boidot R; Bengrine L; Limagne E; Chevriaux A; Vincent J; Ladoire S; Apetoh L; Rébé C; Ghiringhelli F
    Oncotarget; 2016 Feb; 7(8):9309-21. PubMed ID: 26824184
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Pegfilgrastim in Patients Receiving First-Line FOLFOX/Bevacizumab or FOLFIRI/Bevacizumab for Locally Advanced or Metastatic Colorectal Cancer: Final Results of the Pegfilgrastim and Anti-VEGF Evaluation Study (PAVES).
    Pinter T; Klippel Z; Cesas A; Croitoru A; Decaestecker J; Gibbs P; Hotko Y; Jassem J; Kurteva G; Novotny J; O'Reilly S; Salek T; Reiner M; Morrow PK; Choi MR; Whittaker S; Blanke C
    Clin Colorectal Cancer; 2017 Jun; 16(2):103-114.e3. PubMed ID: 28038865
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overview of bevacizumab: a new cancer therapeutic strategy targeting vascular endothelial growth factor.
    Ignoffo RJ
    Am J Health Syst Pharm; 2004 Nov; 61(21 Suppl 5):S21-6. PubMed ID: 15552623
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Managing patients treated with bevacizumab combination therapy.
    Gordon MS; Cunningham D
    Oncology; 2005; 69 Suppl 3():25-33. PubMed ID: 16301833
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of hypertension and proteinuria as markers of efficacy in antiangiogenic therapy for metastatic colorectal cancer.
    Khoja L; Kumaran G; Zee YK; Murukesh N; Swindell R; Saunders MP; Clamp AR; Valle JW; Wilson G; Jayson GC; Hasan J
    J Clin Gastroenterol; 2014; 48(5):430-4. PubMed ID: 24153157
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bevacizumab and oxaliplatin-based chemotherapy in metastatic colorectal cancer.
    Beatty GL; Giantonio BJ
    Expert Rev Anticancer Ther; 2008 May; 8(5):683-8. PubMed ID: 18471041
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bevacizumab safety in Japanese patients with colorectal cancer.
    Hatake K; Doi T; Uetake H; Takahashi Y; Ishihara Y; Shirao K
    Jpn J Clin Oncol; 2016 Mar; 46(3):234-40. PubMed ID: 26774113
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Basal proteinuria as a prognostic factor in patients with metastatic colorectal cancer treated with bevacizumab.
    Uysal M; Bozcuk H; Sezgin Göksu S; Murat Tatli A; Arslan D; Gündüz S; Senol Coskun H; Ozdogan M; Savas B
    Biomed Pharmacother; 2014 May; 68(4):409-12. PubMed ID: 24721326
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integration of novel agents in the treatment of colorectal cancer.
    Iqbal S; Lenz HJ
    Cancer Chemother Pharmacol; 2004 Sep; 54 Suppl 1():S32-9. PubMed ID: 15309512
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma endothelin-1 may predict bevacizumab-induced proteinuria in patients with colorectal cancer.
    Nihei S; Ikeda T; Aoki T; Murasato F; Yaegashi M; Asahi K; Kudo K
    Cancer Chemother Pharmacol; 2023 May; 91(5):427-434. PubMed ID: 37036487
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lack of association of proteinuria and clinical outcome in patients treated with bevacizumab for metastatic colorectal cancer.
    Iwasa S; Nakajima TE; Nagashima K; Honma Y; Kato K; Hamaguchi T; Yamada Y; Shimada Y
    Anticancer Res; 2013 Jan; 33(1):309-16. PubMed ID: 23267162
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation between rash and a positive drug response associated with bevacizumab in a patient with advanced colorectal cancer.
    Saif MW; Longo WL; Israel G
    Clin Colorectal Cancer; 2008 Mar; 7(2):144-8. PubMed ID: 18501075
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monoclonal antibodies targeting vascular endothelial growth factor: current status and future challenges in cancer therapy.
    Hsu JY; Wakelee HA
    BioDrugs; 2009; 23(5):289-304. PubMed ID: 19754219
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinicopathological spectrum of kidney diseases in cancer patients treated with vascular endothelial growth factor inhibitors: a report of 5 cases and review of literature.
    Usui J; Glezerman IG; Salvatore SP; Chandran CB; Flombaum CD; Seshan SV
    Hum Pathol; 2014 Sep; 45(9):1918-27. PubMed ID: 25087655
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.